Newsletter: Healthcare & Life Sciences Update – June 2022

By Craig Townsend, Director of Healthcare at 42T

As we approach the end of H1 2022, I have been thinking more about the COVID-19 pandemic and how it fundamentally changed the economics of healthcare. A lot of people were predicting that the pandemic would lead to a new wave of investment into healthcare and pandemic prevention which led me to write this month’s article. Spoiler alert, investment has dropped back to the pre pandemic baseline, and it turns out the predictions were wrong!

What can we do as healthcare and life science professionals to get more people interested in the medtech space, outside of a global pandemic?

Latest insight from our team

The economics of healthcare 2022

As we learn to live alongside the SARS-CoV-2 Virus, things are returning to ‘normal’ and although there is a significant backlog in health systems around the world, what initiatives is the global healthcare sector focusing on in H1 2022?

Read ‘The economics of healthcare 2022’ article.

Meet the team: Craig Townsend

Position: Director of Healthcare

Joined the team in: July 2021

Specialism/skills: Craig joined us from the world of Venture Capital and is our expert in investment, economics and start-up.

Fun fact: Has over 2,000 film reviews on IMDB!

Find out more about Craig.

And in case you missed these insights from the team…

Medical Device Regulation

This article will give you some good advice on who the regulators are, what differs region to region and some considerations when planning your own regulatory strategy.

View the ‘Medical Device Regulation’ article.

Pre-compliance Testing

Getting pre-compliance testing wrong can result in increased project costs and timescales, mismanaged expectations, and target markets not being achievable.

View the ‘Pre-compliance testing’ article.

Best wishes,

Craig Townsend
Director of Healthcare